| MeSH term | MeSH ID | Detail |
|---|---|---|
| Glioblastoma | D005909 | 27 associated lipids |
| Glioma | D005910 | 112 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
| Hypercholesterolemia | D006937 | 91 associated lipids |
| Hypergammaglobulinemia | D006942 | 9 associated lipids |
| Insulin Resistance | D007333 | 99 associated lipids |
| Leukemia, Myeloid | D007951 | 52 associated lipids |
| Liver Cirrhosis, Experimental | D008106 | 36 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Lupus Erythematosus, Systemic | D008180 | 43 associated lipids |
2E,6E-farnesol
2e,6e-farnesol is a lipid of Prenol Lipids (PR) class. 2e,6e-farnesol is associated with abnormalities such as Granulomatous Disease, Chronic, pathologic fistula and Cavitation. The involved functions are known as Regulation, Metabolic Inhibition, cholesterol biosynthetic process, Process and Transcription, Genetic. 2e,6e-farnesol often locates in Plasma membrane, Cytoplasmic matrix, cornified envelope, Epidermis and peroxisome. The associated genes with 2E,6E-farnesol are RAB3A gene, FOSL1 gene, CASP8AP2 gene, RCC1 gene and GALE gene. The related lipids are Sterols, Membrane Lipids and Steroids.
Cross Reference
Introduction
To understand associated biological information of 2E,6E-farnesol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with 2E,6E-farnesol?
2E,6E-farnesol is suspected in Granulomatous Disease, Chronic, pathologic fistula and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 2E,6E-farnesol
PubChem Associated disorders and diseases
What pathways are associated with 2E,6E-farnesol
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with 2E,6E-farnesol?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with 2E,6E-farnesol?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with 2E,6E-farnesol?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with 2E,6E-farnesol?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with 2E,6E-farnesol?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with 2E,6E-farnesol
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Shack S et al. | Activation of the cholesterol pathway and Ras maturation in response to stress. | 1999 | Oncogene | pmid:10557091 |
| Aizman E et al. | Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes. | 2012 | Oncotarget | pmid:22323550 |
| Mashiach-Farkash E et al. | Computer-based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton. | 2012 | Oncotarget | pmid:22776759 |
| Schmukler E et al. | Ras inhibition enhances autophagy, which partially protects cells from death. | 2013 | Oncotarget | pmid:23370967 |
| Barkan B et al. | Ras inhibition boosts galectin-7 at the expense of galectin-1 to sensitize cells to apoptosis. | 2013 | Oncotarget | pmid:23530091 |
| Faigenbaum R et al. | Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib. | 2013 | Oncotarget | pmid:23530112 |
| Cheng HL et al. | Zoledronate blocks geranylgeranylation not farnesylation to suppress human osteosarcoma U2OS cells metastasis by EMT via Rho A activation and FAK-inhibited JNK and p38 pathways. | 2016 | Oncotarget | pmid:26848867 |
| Hameiri-Grossman M et al. | The association between let-7, RAS and HIF-1α in Ewing Sarcoma tumor growth. | 2015 | Oncotarget | pmid:26393682 |
| Goldshmit Y et al. | Interfering with the interaction between ErbB1, nucleolin and Ras as a potential treatment for glioblastoma. | 2014 | Oncotarget | pmid:25261371 |
| Schmukler E et al. | Chloroquine synergizes with FTS to enhance cell growth inhibition and cell death. | 2014 | Oncotarget | pmid:24368422 |